LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting Click Here
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.
RADNOR, PA / ACCESSWIRE / August 6, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ:DXCM) ("DexCom"). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion.
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting Click Here
NEW YORK CITY, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.
DexCom's latest earnings update was not well-received by the market. The company no longer expects to grow as much as it had hoped.
NEW YORK CITY, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.
RADNOR, PA / ACCESSWIRE / August 4, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ:DXCM) ("DexCom"). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion.
NEW YORK CITY, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.